

Haematologica  
HAEMATOL/2015/128918  
Version 3

The effects of JAK inhibitor therapy upon novel markers of thrombosis  
in myeloproliferative neoplasms

Disclosures: Clodagh Keohane: No relevant disclosures; Donal McLornan: Speaker fees from Novartis. Katy Sanchez: No relevant disclosures. Christopher Connor: No relevant disclosure. Deepti Radia: Speaker fees from Novartis. Claire N Harrison: Speaker fees and funding from Novartis and Sanofi. This work was supported by a grant from Gabrielle's Angel Foundation for Cancer Research UK.

Contributions: C.K was involved with all aspects of the study's design, execution, analysis, and manuscript preparation. C.H and DM contributed equally to study design, manuscript preparation and project leadership. K.S and C.C contributed to flow cytometry execution and expert analysis. D.R contributed to clinical details.